---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Natural history, survival, and mortality"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Natural history, survival, and mortality. Topics: Progression to metastatic castration-resistant disease as the cause of prostate cancer death; Modeled share of U.S. prostate cancer deaths occurring in metastatic castration-resistant states; Estimated U.S. deaths in 2026, all prostate cancer stages; U.S. prostate cancer mortality trend, all stages; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Progression to metastatic castration-resistant disease as the cause of prostate cancer death

> “Prostate cancer deaths are typically the result of progression to metastatic castration-resistant prostate cancer (mCRPC).”

Source: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer)

<a id="topic-2.2.1.3-2"></a>

### Modeled share of U.S. prostate cancer deaths occurring in metastatic castration-resistant states

> “All-cause mortality in prostate cancer was estimated at 168,290 in 2009 and 219,360 in 2020, with 20.5% and 19.5% of these deaths, respectively, occurring in men with mCRPC.”

Source: [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/)

<a id="topic-2.2.1.3-3"></a>

### Estimated U.S. deaths in 2026, all prostate cancer stages

| Measure | Quoted value |
| --- | --- |
| Estimated deaths from prostate cancer, United States, 2026 | “36,320” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

> “Prostate cancer is the second-leading cause of cancer death in men in the US, behind only lung cancer. About 1 in 49 men will die of prostate cancer.”

Source: [American Cancer Society (2026)](https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html)

<a id="topic-2.2.1.3-4"></a>

### U.S. prostate cancer mortality trend, all stages

> “Increased incidence also may be contributing to a deceleration in the decline for prostate cancer mortality, from 3.5% per year during the late 1990s and 2000s to 0.6% per year from 2012 through 2023 (Table 8, Figure 5).”

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.3-5"></a>

### Distant-stage five-year relative survival, all metastatic prostate cancer

| SEER measure | Quoted value |
| --- | --- |
| Distant-stage five-year relative survival | “40.1%” |

Source: [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html)

<a id="topic-2.2.1.3-6"></a>

### Overall survival in metastatic castration-resistant prostate cancer, U.S. Flatiron cohort 2016 to 2023

> “Overall median OS was 24.6 months and trended lower for patients who received prior ARPi only or both prior ARPi and taxane.”

Source: [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/)

<a id="topic-2.2.1.3-7"></a>

### Overall survival in metastatic castration-resistant prostate cancer, Medicare fee-for-service cohort 2014 to 2019

> “Overall mortality in the cohort was 54%. Median survival from mCRPC diagnosis was 25.6 months (95% confidence interval [CI] 25.0–26.2 months) (Fig. 3). Median survival from treatment initiation was 23.4 months (95% CI: 22.8–24.1 months)”

Source: [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-2.2.1.3-8"></a>

### Overall survival in metastatic castration-resistant prostate cancer after metastatic hormone-sensitive disease, U.S. ConcertAI cohort 2020 to 2023

> “Median real-world overall survival was 27.2 months from mCRPC diagnosis and 20.8 months from 1L therapy.”
> “Back-to-back ARPI use from mHSPC to mCRPC is common in current clinical practice and survival remains <3 years.”

Source: [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/)

<a id="topic-2.2.1.3-9"></a>

### Real-world overall survival across observational studies

> “Median RW OS was ≤34 mo from either mCRPC diagnosis or initiation of first-line mCRPC treatment in most studies.”

Source: [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/)

<a id="topic-2.2.1.3-10"></a>

### Overall survival after an androgen receptor pathway inhibitor and a taxane, standard-of-care arm of a phase 3 trial

> “The median overall survival among all 831 patients who had undergone randomization was 15.3 months in the 177Lu-PSMA-617 group, as compared with 11.3 months in the control group (hazard ratio for death, 0.62; 95% CI, 0.52 to 0.74; P<0.001 [significance level, 0.05])”

Source: [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/)

<a id="topic-2.2.1.3-11"></a>

### Overall survival by site of metastasis, docetaxel-treated trial participants

> “Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with men with liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months.”

Source: [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/)

<a id="topic-2.2.1.3-12"></a>

### Survival with castration-resistant prostate cancer before current therapies

> “The median survival of patients with CRPC was reported in five studies, with values varying from 9 to 30 months.”

Source: [Kirby et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21995694/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
